Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,459.82 -9.48 (-0.17%) Dow
39,055.96 -56.20 (-0.14%) Nasdaq
17,733.82 +16.17 (+0.09%) Bitcoin USD
61,705.64 -16.48 (-0.03%) CMC Crypto 200
1,278.77 -5.02 (-0.39%)
CORT Jul 2024 28.000 call
- GlobeNewswire
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetesResults demonstrate a hypercortisolism prevalence rate of 24 percent in this p
- Insider Monkey
What Makes Corcept Therapeutics (CORT) a Good Investment Bet?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Value Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The firm focuses on companies with strong balance sheets and attractive cash flows with compelling valuations rather than following market trends. The strategy outperformed the benchmark Russell 2000 Value […]
- Zacks
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
